CurrentCignaPolicy N/A

Cigna Medical Coverage Policy- Therapy Services Low-Level Laser and High-Power Laser Therapy

Defines Cigna's coverage position for low-level laser therapy (LLLT) and high-power Class IV therapeutic laser light therapy across indications, documentation requirements, coding guidance, and clinical background. This part includes policy determination of medically necessary vs not medically necessary/unproven uses and relevant CPT/HCPCS codes.

Policy Summary

PayerCigna

PolicyCigna Medical Coverage Policy- Therapy Services Low-Level Laser and High-Power Laser Therapy

Policy CodePolicy N/A

Change TypeNo material change

Effective Date3/15/2026

Next Review Date3/15/2027

Key ActionDocument supporting medical necessity, diagnosis/reason for treatment, duration and specific parameters used, area treated, observations pre/post treatment, and demonstration of improvement or lack thereof including symptoms and functional changes.

SourceLink

POLICY UPDATE CHANGES

No material clinical/coverage changes reported in this update.

1Medically necessary indication (oral mucositis prevention)

4Not medically necessary example indications listed

1Therapy type considered experimental (Class IV HILT)

8Conditions discussed

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Typical timeframe of reported benefit

Coverage Summary

Scope: This policy defines Cigna's coverage position for low-level laser therapy (LLLT) (also called cold laser, photobiomodulation/PBM) and high-power Class IV therapeutic laser light therapy, including distinctions from surgical (hot) lasers and related device classifications. Effective date: 2026-03-15. Next review date: 2027-03-15. Overall coverage stance: mixed—LLLT is medically necessary only for one specific indication and otherwise not covered, while high-power Class IV therapeutic laser therapy is considered experimental/investigational/unproven for all indications. Medically necessary indication: prevention of oral mucositis in patients undergoing cancer treatment associated with increased risk (including chemotherapy, radiotherapy, and/or hematopoietic cell transplantation).

Key policy quick facts

Medically necessary indicationPrevention of oral mucositis in patients undergoing cancer treatment (including chemotherapy, radiotherapy, and/or hematopoietic cell transplantation)

Experimental / unproven stanceHigh‑power Class IV therapeutic laser light therapy considered experimental/investigational/unproven for all indications

Not medically necessary (examples)Wound healing; musculoskeletal pain (eg, back/neck pain, carpal tunnel, lateral epicondylitis, shoulder impingement, myofascial pain, fibromyalgia); osteoarthritis and rheumatoid arthritis; temporomandibular joint disorders

Documentation / device noteLLLT defined as low‑power/cold laser (nonthermal); several LLLT and some high‑power devices have FDA 510(k) listings but high‑power Class IV uses remain unproven

Next review2027-03-15

Medical-Necessity Criteria

Medically Necessary

Low-level laser therapy is considered medically necessary when ALL of the following are met:

ALL of the following

Service is low-level laser therapy (LLLT; also referred to as cold laser therapy, low-power laser therapy, low-intensity laser, low-energy laser therapy).
Indication is prevention of oral mucositis in patients undergoing cancer treatment associated with increased risk of oral mucositis, including chemotherapy and/or radiotherapy, and/or hematopoietic cell transplantation.

Not Medically Necessary

Low-level laser therapy (LLLT) is considered not medically necessary for any other indication, including but not limited to:

ANY of the following

Evidence-based Findings by Condition

Evidence scope: The literature spans many device types and clinical indications with substantial heterogeneity in devices, wavelengths, energy/dosing, and application methods; trial quality varies and many studies are small or short-term. Some randomized trials and systematic reviews report short-term symptom benefits for select musculoskeletal and soft-tissue conditions, but results are inconsistent across studies and indications. Adherence to dosing frameworks (for example WALT parameters) and other protocol details materially affects outcomes, and optimized parameter selection (wavelength, energy density/J·cm2, number and frequency of sessions) is important to reproduce benefit. Full evidence summaries, systematic reviews, meta-analyses, and guideline recommendations are provided in the Evidence section of the policy.

Evidence-based Findings by Condition

Summaries of evidence (systematic reviews, meta-analyses, RCTs, and guidelines) indicating strength and direction of effect for laser therapies by condition:

ANY of the following

Low back pain: Evidence inconsistent; for acute low back pain evidence insufficient. For chronic low back pain some trials show LLLT more effective than sham for pain (SOE low), mixed effects for function; evidence limited, small trials, short-term effects.
HILT for back pain:

Coding Information

FDA 510(k) cleared high-power therapeutic laser systems (examples)mixed

Diowave Laser System / AVI HP-7.5 / AVI HPLL-12	Diawave Lasers (formerly Avicenna Laser Technology Inc.) 510(k) cleared as 'Infrared lamp' for topical heating/therapeutic relief
OptonPro	Zimmer MedizinSystems 510(k) cleared device

Provider Actions and Documentation

Documentation Required

Documentation requirements for laser therapy

Document supporting medical necessity, diagnosis/reason for treatment, duration and specific parameters used, area treated, observations pre- and post-treatment, and demonstration of improvement or lack thereof including symptoms and functional changes.

Examples: diagnosis, reason/purpose for treatment; duration and specific parameters used; area treated; observations pre/post treatment; demonstration of improvement or lack thereof (symptoms and functional changes).

Billing Rule

Use covered diagnosis and procedure codes

Reimbursement is provided only if the requested services are submitted with the covered diagnosis and/or procedure codes listed in the Coding Information section. Claims submitted without the covered codes under this policy will be denied as not covered.

Definitions and Reported Treatment Thresholds

Key definitions and device distinctions: Low-level laser therapy (LLLT) / photobiomodulation (PBM) refers to nonthermal, non-ablative lower-power laser or LED light intended to modulate cellular responses to reduce pain/inflammation and promote tissue repair (terms include cold laser, low-power/intensity/energy laser). High-intensity or high-power laser therapy (HILT / High Power Class IV therapeutic laser light therapy) denotes devices producing substantially higher continuous power (manufacturer examples ~7,500 mW) intended for deeper penetration and larger surface treatment, which can produce thermal/topical heating effects and are cleared in some cases as 'infrared lamp' for topical heating/temporary relief. Policy-relevant distinction: LLLT/PBM is characterized as nonthermal photobiomodulation, while high-power/Class IV systems are thermal or higher-power modalities and are considered experimental/investigational/unproven for all indications per this policy.

Key thresholds / parameter ranges

Wavelength ranges (reported)Intraoral OM: 620–750 nm; optimal OM intraoral 630–670 nm and extraoral 780–850 nm; TMD examples: 690–810 nm and 810–940 nm; some TMD/Higher‑wavelength studies 910–1100 nm

Energy density / fluenceCommon reported ranges: 2–6 J/cm2 (OM umbrella/umbrella review); 3–12 J/cm2 (TMD); BCRL axillary protocols 1.5–2 J/cm2

LLLT power ranges for OMHe‑Ne or InGaAlP lasers with power ~10–25 mW reported favorable for OM prevention/treatment

Selected Evidence Highlights

Topic	Key finding / implication
Oral mucositis (MASCC/ISOO)	MASCC/ISOO and multiple meta‑analyses recommend intraoral photobiomodulation/LLLT for prevention of oral mucositis in HSCT and head & neck radiotherapy patients; trials show reduced incidence, severity, duration and pain.
Plantar fasciitis	Multiple RCTs and meta‑analyses (eg Guimarães 2022/2023; Ferlito 2023) report LLLT/PBMT reduces short‑term pain (moderate‑quality evidence) and may reduce disability; can be considered a component of care.
TMD	Numerous systematic reviews and RCTs show heterogeneous results but many trials report short‑term pain reduction and improved mouth opening with LLLT/HILT; evidence quality variable and protocol heterogeneity limits conclusions (Díaz 2025, multiple reviews).
Wound healing (DFU)	Meta‑analyses (Huang 2021; Liu 2023; Zhang 2024; Chen 2025) report higher complete healing rates, reduced ulcer area and shorter healing time with red/IR LLLT/HILT but evidence quality often low to very low; promising but more high‑quality trials needed.
Low back pain	Systematic reviews and AHRQ find inconsistent evidence: insufficient for acute LBP and low to insufficient SOE for chronic LBP; some small trials show short‑term pain benefit for LLLT/HILT (SOE low), often small effects and heterogeneity in parameters.
BCRL	Systematic reviews and RCTs show conflicting results with low to very low certainty; some regimens (axillary‑targeted, 3×/week, 1.5–2 J/cm2, >15 sessions) report reduced swelling and improved QOL but overall evidence is uncertain.
Painful diabetic neuropathy	Guideline (Bril et al. 2011) states LLLT is probably not effective and is not recommended for painful diabetic neuropathy.
FDA 510(k) summaries	Multiple LLLT devices received FDA 510(k) clearance (eg MicroLight 830, Thor Laser, Luminex, Vectra Genisys) as Class II 'Lamp, Non‑heating, for Adjunctive Use in Pain Therapy'; some high‑power systems cleared as 'Infrared lamp' for topical heating with limited clinical trial data submitted to FDA.

Revision History

Policy Summary

PayerCigna

PolicyCigna Medical Coverage Policy- Therapy Services Low-Level Laser and High-Power Laser Therapy

Policy CodePolicy N/A

Change TypeNo material change

Effective Date3/15/2026

Next Review Date3/15/2027

SourceLink

On This Page

Musculoskeletal pain (e.g., back and neck pain, carpal tunnel syndrome, lateral epicondylitis, shoulder impingement, myofascial pain syndrome, fibromyalgia and others)

Osteoarthritis and rheumatoid arthritis

Temporomandibular joint disorders

Experimental, Investigational, and/or Unproven

High-power Class IV therapeutic laser light therapy or similar therapeutic laser light therapy is considered experimental, investigational, and/or unproven for all indications.

Any use of high-power Class IV therapeutic laser light therapy (including devices described as High Power Class IV producing ~7,500 milliwatts continuous power) is experimental/investigational/unproven regardless of indication.

High-intensity laser therapy (HILT) for chronic back pain: Small studies (e.g., n=20) show within- and between-group improvements versus conservative therapy; overall evidence limited but some meta-analyses/reviews report HILT and LLLT as effective adjuncts to exercise.

Neck pain: Systematic reviews inconsistent; moderate SOE for short-term improvement in chronic neck pain with LLLT (improved pain and function); some reviews report LLLT not effective for persistent NAD I-II, while pooled evidence suggests short-term benefit.

Achilles tendinopathy: Small trials show some benefit when LLLT added to eccentric exercise; evidence low to very low certainty; insufficient to support routine use.

Plantar fasciitis: Multiple RCTs/meta-analyses indicate LLLT reduces short-term pain (moderate-quality evidence) and may reduce disability short- to medium-term; may be considered a component of care.

Lateral epicondylitis (tennis elbow): Systematic reviews inconsistent; some evidence for short-term pain relief and function improvement; overall inconclusive with heterogeneous results.

Rheumatoid arthritis: Mixed/low-quality evidence; older Cochrane review found inconclusive results due to heterogeneity; some guidelines/reporting suggest possible benefit in subgroups but overall insufficient firm documentation.

Temporomandibular disorders (TMD/TMJ): Multiple systematic reviews and meta-analyses with heterogeneous results; many trials show reduced pain and some functional improvement short-term; evidence quality variable and many studies high risk of bias; some guidelines conditionally recommend against LLLT for chronic TMD within broader recommendations.

Guidelines and regulatory context: Clinical guideline bodies (notably MASCC/ISOO) support the use of intraoral photobiomodulation (PBM/LLLT) for prevention of oral mucositis in specified oncology settings. For other indications such as wound healing, musculoskeletal conditions, TMD, and lymphedema, the evidence is mixed or low certainty. Multiple systematic reviews/meta-analyses and FDA 510(k) device clearances relevant to LLLT and some high-power devices are summarized in the policy's Evidence section.

Covered codes: 97037, 0552T, S8948
Use of 97039 (unlisted modality) to report high-power Class IV therapeutic laser light therapy is considered experimental/unproven and will be denied

Documentation Required

Record of clinical indication and treatment parameters

Because effectiveness varies by condition and laser parameters, document the clinical indication and the specific laser modality (LLLT vs HILT), wavelength, dosage (Joules or J/cm2), number and frequency of sessions, and any concurrent therapies (for example, exercise or other rehabilitation) in the medical record.

Documentation Required

Protocol adherence and parameter documentation

When using photobiomodulation/LLLT for oral mucositis, temporomandibular disorders, wound healing or breast cancer–related lymphedema, document the exact device parameters (wavelength, energy density/fluence, power, number of sessions, frequency, and anatomical target) and ensure adherence to published protocol ranges noted in guidelines and reviews to optimize reproducibility and efficacy.

Documentation Required

Inform patients about benefits and uncertainties

Inform patients about the expected benefits and potential uncertainties or risks of therapy, and specifically advise oncology patients about conflicting animal data on tumor behavior when using PBM/LLLT; emphasize that protocol adherence is important.

Note

Device 510(k) status and indication awareness

Be aware that several LLLT and some high-power laser devices have received FDA 510(k) clearance for adjunctive pain therapy or topical heating; clinical trial data submitted to FDA may be limited and not always published in peer-reviewed literature.

Examples of 510(k) cleared LLLT devices: MicroLight 830; Thor Laser System; Luminex LL Laser System; Vectra Genisys Laser System
Examples of high-power systems cleared as 'Infrared lamp' for topical heating: Diowave (AVI HP-7.5, AVI HPLL-12); OptonPro

Session number / duration patterns>15 total sessions and 3×/week associated with better BCRL outcomes; longer treatment (>4 weeks) associated with more sustained TMD benefits; some KOA/tendinopathy trials used 8–16 sessions over 2–8 weeks

WALT / dosing guidanceWALT recommends power densities <100 mW/cm2 for superficial tendons, energy dose 1–8 J; deeper tendons up to 600 mW/cm2 and 3–9 J; wavelengths 780–904 nm per WALT